HIV hastalarında antiretroviral tedavinin lenfosit alt grup ve CD38 ile HLADR üzerine etkisi
Loading...
Files
Date
2023
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Hatay Mustafa Kemal Üniversitesi
Access Rights
info:eu-repo/semantics/openAccess
Abstract
İnsan immün yetmezlik virüsü (HIV) kişilerin immün sistemini hedef alan ve AIDS 'e neden olan bir hastalıktır. Bu çalışmada HIV pozitif bireylerde antiretroviral tedavinin lenfosit alt gruplar ile T hücre aktivasyon belirteçlerinden olan CD38 ve HLADR üzerine etkisinin akım sitometri ile araştırılması amaçlanmıştır. Çalışmaya HIV pozitif saptanan 30 yeni hasta, 3 ay rutin anti-viral tedavi almış 30 takip hastası ve 20 sağlıklı birey kontrol grubu olarak dâhil edildi. Tüm bireylerden akım sitometri ve hemogram ölçümleri için EDTA'lı tüplere tam kan örnekleri alındı. Tam kan örneklerinde hemogram ölçümleri yapıldı ve aynı örnekte T, B, NK ve T lenfosit alt gruplarının yüzdeleri akım sitometrik yöntem ile ölçüldü. Absolut sayıları double platform yöntemine göre hesaplandı. Ayrıca T hücrelerinde CD38 ve HLA-DR aktivasyon belirteçleri akım sitometri yöntemiyle analiz edildi. Rutin biyokimya parametreleri spektrofotometrik yöntemle otoanalizörde ölçüldü. IL-2 düzeyleri ELISA yöntemiyle çalışıldı. CD4/CD8 oranı ile CD4+ T hücre sayısı ve CD4+/CD38+ hücre yüzdesi Yeni Tanı grubunda kontrole göre anlamlı derecede düşük (Sırasıyla, p=0.022, p=0.001, p=0.026) iken CD8+ T hücre sayısı ve CD8+/CD38+ ve CD8+/HLADR+ hücre yüzdesi anlamlı derecede yüksekti (sırasıyla, p=0.011, p<0.001). Tedavi sonrası grupta ise CD4+ hücre sayısı ve CD4+/CD38+ yüzdesi Yeni Tanı grubuna göre anlamlı derecede yüksek iken (sırasıyla, p=0.001, p=0.006), CD8+/CD38+ ve CD8+/HLADR yüzdesinde anlamlı azalma saptandı (p<0.001, p=0.003). Tedavi sonrasında CD8+ T hücrelerin absolut sayısında değişiklik saptanmadı. CD4+/HLADR yüzdesinde anlamlı fark yoktu. Serum IL-2 değerleri ise sadece Tedavi alan grupta anlamlı derecede düşüktü. CD8+ T hücreleri üzerinde CD38 ve HLA-DR MFI değerleri HIV enfekte hastalarda arttığı ve ART sonrasında azaldığı gözlemlenmiştir. Buna göre HIV hastlarının tanı ve takibinde CD4+ T hücre absolute sayılarının incelenmesi yanında CD8+ T hücreleri üzerindeki aktivasyon antijenlerinden CD38 ve HLADR'nin hem yüzde hem de MFI değerleri de göz önünde bulundurulmalıdır. Ayrıca ART etkinliğinin değerlendirilmesinde de bu iki aktivasyon parametresinin ilave bir belirteç olarak potansiyel taşıdığını düşünmekteyiz.
Human immunodeficiency virus (HIV) is a disease that targets the immune system of people and causes AIDS. In this study, it was aimed to investigate the effect of antiretroviral therapy on lymphocyte subgroups and T cell activation markers CD38 and HLADR in HIV positive individuals by flow cytometry. Thirty new HIV-positive patients, 30 follow-up patients who received 3 months of routine antiviral therapy, and 20 healthy individuals were included in the study as a control group. Whole blood samples were taken from all individuals in EDTA tubes for flow cytometry and hemogram measurements. Hemogram measurements were made in whole blood samples and the percentages of T, B, NK and T lymphocyte subgroups were measured by flow cytometric method in the same sample. Absolut methods were calculated according to the double platform method. In addition, CD38 and HLA-DR activation markers in T cells were analyzed by flow cytometry. Routine biochemistry data were measured in a spectrophotometric color autoanalyzer. IL-2 levels were studied by ELISA method. While CD4/CD8 ratio and CD4+ T cell count and CD4+/CD38+ cell percentage were significantly lower in the Newly Diagnosed group than in the control group (respectively, p=0.022, p=0.001, p=0.026), CD8+ T cell count and CD8+/CD38+ and CD8+/HLADR+ cells percentage was significantly higher (p=0.011, p<0.001, respectively). In the post-treatment group, while the CD4+ cell count and CD4+/CD38+ percentage were significantly higher than the Newly Diagnosed group (p=0.001, p=0.006, respectively), a significant decrease was found in the percentages of CD8+/CD38+ and CD8+/HLADR (p<0.001, p=0.006, p=0.003). There was no change in the absolute number of CD8+ T cells after treatment. There was no significant difference in the percentage of CD4+/HLADR. Serum IL-2 values were significantly lower only in the treatment group. It was observed that CD38 and HLA-DR MFI values on CD8+ T cells increased in HIV infected patients and decreased after ART. Accordingly, in the diagnosis and follow-up of HIV patients, besides examining the absolute numbers of CD4+ T cells, both the percent and MFI values of CD38 and HLADR, which are activation antigens on CD8+ T cells, should also be considered. In addition, we think that these two activation parameters have potential as an additional marker in the evaluation of the efficacy of ART.
Human immunodeficiency virus (HIV) is a disease that targets the immune system of people and causes AIDS. In this study, it was aimed to investigate the effect of antiretroviral therapy on lymphocyte subgroups and T cell activation markers CD38 and HLADR in HIV positive individuals by flow cytometry. Thirty new HIV-positive patients, 30 follow-up patients who received 3 months of routine antiviral therapy, and 20 healthy individuals were included in the study as a control group. Whole blood samples were taken from all individuals in EDTA tubes for flow cytometry and hemogram measurements. Hemogram measurements were made in whole blood samples and the percentages of T, B, NK and T lymphocyte subgroups were measured by flow cytometric method in the same sample. Absolut methods were calculated according to the double platform method. In addition, CD38 and HLA-DR activation markers in T cells were analyzed by flow cytometry. Routine biochemistry data were measured in a spectrophotometric color autoanalyzer. IL-2 levels were studied by ELISA method. While CD4/CD8 ratio and CD4+ T cell count and CD4+/CD38+ cell percentage were significantly lower in the Newly Diagnosed group than in the control group (respectively, p=0.022, p=0.001, p=0.026), CD8+ T cell count and CD8+/CD38+ and CD8+/HLADR+ cells percentage was significantly higher (p=0.011, p<0.001, respectively). In the post-treatment group, while the CD4+ cell count and CD4+/CD38+ percentage were significantly higher than the Newly Diagnosed group (p=0.001, p=0.006, respectively), a significant decrease was found in the percentages of CD8+/CD38+ and CD8+/HLADR (p<0.001, p=0.006, p=0.003). There was no change in the absolute number of CD8+ T cells after treatment. There was no significant difference in the percentage of CD4+/HLADR. Serum IL-2 values were significantly lower only in the treatment group. It was observed that CD38 and HLA-DR MFI values on CD8+ T cells increased in HIV infected patients and decreased after ART. Accordingly, in the diagnosis and follow-up of HIV patients, besides examining the absolute numbers of CD4+ T cells, both the percent and MFI values of CD38 and HLADR, which are activation antigens on CD8+ T cells, should also be considered. In addition, we think that these two activation parameters have potential as an additional marker in the evaluation of the efficacy of ART.
Description
Keywords
Biyokimya, Biochemistry
